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ABSTRACT
Neurocognitive deficits are serious sequelae that follow cranial irradiation used 
to treat patients with medulloblastoma and other brain neoplasms. Cranial irradiation 
causes apoptosis in the subgranular zone of the hippocampus leading to cognitive 
deficits. Valproic acid (VPA) treatment protected hippocampal neurons from radiation-
induced damage in both cell culture and animal models. Radioprotection was observed 
in VPA-treated neuronal cells compared to cells treated with radiation alone. This 
protection is specific to normal neuronal cells and did not extend to cancer cells. 
In fact, VPA acted as a radiosensitizer in brain cancer cells. VPA treatment induced 
cell cycle arrest in cancer cells but not in normal neuronal cells. The level of anti-
apoptotic protein Bcl-2 was increased and the pro-apoptotic protein Bax was reduced 
in VPA treated normal cells. VPA inhibited the activities of histone deacetylase (HDAC) 
and glycogen synthase kinase-3β (GSK3β), the latter of which is only inhibited in 
normal cells. The combination of VPA and radiation was most effective in inhibiting 
tumor growth in heterotopic brain tumor models. An intracranial orthotopic glioma 
tumor model was used to evaluate tumor growth by using dynamic contrast-enhanced 
magnetic resonance (DCE MRI) and mouse survival following treatment with VPA and 
radiation. VPA, in combination with radiation, significantly delayed tumor growth and 
improved mouse survival. Overall, VPA protects normal hippocampal neurons and 
not cancer cells from radiation-induced cytotoxicity both in vitro and in vivo. VPA 
treatment has the potential for attenuating neurocognitive deficits associated with 
cranial irradiation while enhancing the efficiency of glioma radiotherapy.
INTRODUCTION
Radiotherapy, the clinical application of ionizing 
radiation, is a crucial treatment option in modern cancer 
therapy in addition to surgery and systemic therapy. This is 
corroborated by the fact that more than 60% of all cancer 
patients receive radiotherapy [1, 2]. Cranial irradiation 
is commonly used for the treatment of neoplasms 
involving the central nervous system. Radiotherapy 
can have negative sequelae of acute neurocognitive 
deficits, especially in the pediatric population [3–5]. 
The pathogenesis of radiation-induced neurocognitive 
deficits involves apoptosis of neuroproliferative cells in 
the subgranular zone of the hippocampus, a region in 
the brain vital for learning and memory [6–11]. Several 
studies have demonstrated a steep, long-term decline in 
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subgranular neurogenesis in the dentate gyrus following 
radiation exposure [11–15] and direct irradiation of the 
hippocampus has been shown to result in pronounced 
cognitive deficits [16]. The cognitive deficits following 
hippocampal irradiation include deficits of learning, 
memory, and spatial processing [17, 18]. Other areas 
of the cerebrum appear to be less sensitive to the 
effects of radiation [19]. Although at present there is no 
pharmacological prophylaxis available for the prevention 
of radiation-induced neurocognitive deficits, the drugs 
memantine and minocycline are promising novel agents. 
Memantine attenuated cognitive function decline after 
whole brain radiotherapy (WBRT) in patients with brain 
metastases [20]. Minocycline ameliorated cognitive 
impairment induced by WBRT in animal models [21].
Valproic acid (VPA) is a short branched–chain 
carboxylic acid that is an FDA approved anti-seizure 
and antidepressant drug that is well tolerated and whose 
toxicity profile has been extensively characterized [22]. 
VPA has a neuroprotective effect in the setting of 
various neurological insults, including ibetinoic 
acid [23], glutamate toxicity [24, 25], intracerebral 
hemorrhage [26], ischemia [27, 28], malonate 
toxicity [29], and oxidative stress [30]. The inhibition of 
histone deacetylase (HDAC) activity by VPA is thought 
to be involved in such neuroprotection [24–27, 31–34]. 
VPA inhibits both class I and II HDACs with resultant 
hyperacetylation of histone H3 and H4 [35–39]. In 
addition to HDAC inhibition, VPA has been shown to 
have effects on the Akt/GSK3β pathway, an observation 
that provides a novel facet of mechanisms involved in 
the neuroprotective effects of VPA [40]. Other pathways 
have also been proposed, including the induction of alpha-
synuclein [24], heat shock protein 70 [34], brain-derived 
neurotrophic factor [41], and modulation of the JNK 
pathway [42].
In addition to protecting healthy neurons, treatment 
with VPA can selectively kill various cancer cell lines 
including glioblastoma [43–45], erythroleukemic cells 
[43], colon cancer cells [46] and prostate cancer cells [47]. 
The preclinical data of VPA on 19 different types of solid 
cancers including glioma have been summarized [48, 49]. 
The mechanism of sensitization is proposed to involve 
inhibition of HDAC leading to interference with the repair 
of double strand DNA breaks [50–53]. VPA is also known 
to inhibit cell growth in cancer cells by inducing apoptosis 
and cell cycle arrest [54, 55].
GBM patients treated with VPA as an anticonvulsant 
agent during treatment with radiochemotherapy have 
recently drawn attention because of better outcomes of 
the treatment, reviewed in [56]. Combined therapy with 
VPA produced a 3-month longer overall survival (OS) as 
compared with carbamazepine in patients with GBM [57]. 
Several recent studies have found improved OS in both 
children and adults, ranging from 3–6 months by the 
inclusion of VPA [48, 58–61]. It has been speculated that 
the HDAC inhibitory properties of VPA could mediate the 
prolonged survival derived from radio-chemotherapy seen 
in GBM patients [62].
Whole genome expression monitored by microarray 
analysis of primary tumors of patients treated with VPA 
showed significant up-regulation of hundreds of genes 
belonging to multiple pathways. These include ribosomal 
proteins, oxidative phosphorylation, MAPK signaling, 
focal adhesion, cell cycle, antigen processing and 
presentation, proteasome, apoptosis, PI3K, Wnt signaling, 
calcium signaling, TGF-beta signaling, and ubiquitin-
mediated proteolysis among others [49].
In the present study, we found that VPA protected the 
normal hippocampus from radiation-induced damage, while 
sensitizing malignant gliomas to radiation. We analyzed 
the anti-apoptotic effects of VPA administration in vitro 
and in vivo and characterized the changes in intracellular 
signaling and protein expression induced by administration 
of VPA prior to radiation. We also determined the 
radiosensitizing effect of VPA in glioblastoma cell lines, 
and its effects on tumor growth delay and survival of 
intracranial glioma-bearing mice using dynamic contrast 
enhanced magnetic resonance imaging, DCE MRI.
RESULTS
VPA treatment protects hippocampal neurons 
from radiation-induced apoptosis in vivo
To determine whether VPA regulates cell survival 
and apoptosis in the subgranular zone of the hippocampus 
after irradiation, we pretreated 1-week-old mice with 
300 mg/kg of VPA for 7 days prior to cranial irradiation 
with 7Gy. Typically, glioblastoma patients are treated with 
fractionated focal irradiation delivered as daily fractions 
of 2 Gy given five days per week for 6 weeks, for a total 
of 60 Gy [63]. We have shown that treatment with 7 Gy 
is in the steep part of the sigmoidal dose response curve 
for radiation-induced apoptosis in the mouse hippocampus 
[64] and hence we used 7 Gy for our studies. Apoptosis 
within the subgranular zone was determined by staining 
the hippocampal sections with a TUNEL kit, and the 
TUNEL positive cells (TPC) were counted (Figs. 1A 
& 1B). Three sections from each of three different mice 
in each treatment (a total of 9 sections per treatment) 
were analyzed. Mice irradiated with 7Gy had increased 
apoptosis compared to untreated mice. Mice treated with 
VPA prior to 7Gy irradiation had significantly fewer 
TPC compared to mice irradiated with 7 Gy (P < 0.001; 
Fig. 1B), indicating that VPA treatment protected the 
mouse hippocampus from radiation-induced apoptosis.
VPA treatment attenuates radiation-induced 
apoptosis in HT22 cells
We monitored radiation-induced apoptosis in vitro 
by staining irradiated normal hippocampal HT22 cells 
with Annexin V-APC and propidium iodide. The stained 
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Figure 1: VPA treatment protects hippocampal neurons from radiation-induced apoptosis in vivo and modulates the 
expression of apoptotic signaling proteins in vitro. A. One-week-old C57BL/6 mice pups were treated with daily i.p. injections of 
VPA (300 mg/kg) or PBS for 7 days. One hour after the last VPA treatment, the pups heads were irradiated with 7 Gy while the rest of the 
body was shielded with lead. Twenty-four hours later, the animals were sacrificed and brains were fixed and coronally sectioned. Sections 
that contained hippocampus were stained with TUNEL. Shown are representative photographs of mouse hippocampus. The arrows indicate 
examples of TUNEL positive cells (TPC). B. Eight HPF at 200x magnification were evaluated and TPC were counted for each experimental 
group. Shown is the average number of TPC per HPF for each radiation dose group (SD of three independent experiments, *P < 0.05). 
C. HT22 cells were treated with PBS or 0.6 mM VPA for 7 days prior to irradiation with 4 Gy. 24 h after irradiation, cells were stained with 
Annexin V-APC/propidium iodide and analyzed by flow cytometry; *P < 0.05 D. Cells were fixed and stained with DAPI, and apoptotic 
cells were counted in eight randomly selected HPF at 200X magnification. Shown are bar graphs of the average percent of apoptotic cells 
for each treatment with SD from three experiments; *P < 0.05. E. HT22 cells were treated with PBS or 0.6 mM VPA for 7 days prior to 
irradiation with 4 Gy. Whole cell extracts were immunobloted to determine the levels of Bax and Bcl-2. Actin was used to normalize the 
protein loading in each lane. Densitometry values representing the ratio of the various proteins normalized actin is indicated below each 
immunoblot.
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cells were analyzed by flow cytometry after various 
experimental treatments (Fig. 1C). Cells pre-treated 
with VPA prior to 4Gy irradiation had significantly less 
apoptotic cells (12% annexin V positive: P = 0.002), 
than cells treated with PBS alone (50%; Fig. 1C). To 
further confirm these results, we monitored the nuclear 
morphology of irradiated cells using DAPI staining 
(Supplemental Fig. 1, Fig. 1D). Pre-treatment of irradiated 
HT22 cells with VPA led to a protective effect, with a 
reduced number of apoptotic cells (15%) compared to 
35% in PBS-pretreated cells (P < 0.001; Fig. 1D). We 
did observe a slight increased apoptosis when cells were 
treated with VPA when compared to PBS; this however 
was not statistically significant. Treatment of HT22 cells 
with VPA led to decreased levels of the pro-apoptotic 
protein BAX and increased levels the anti-apoptotic 
protein Bcl-2 (Fig. 1E), which is consistent with the 
results obtained using the other endpoints for apoptosis 
described above. However, we did not detect any PARP 
cleavage in irradiated HT22 cells as has been reported 
before (Supplementary Fig. 2) [65].
VPA treatment reduces GL261 cell survival
To determine the effect of VPA treatment on cell 
viability and survival of hippocampus-derived HT22 cells 
and glioblastoma GL261 cells, we performed a colony 
formation assay. Cells were treated with 0.6 mM VPA or 
PBS for 7 days and equal numbers of cells were plated 
to determine plating efficiency. There was no significant 
difference in the numbers of colonies from HT22 cells 
treated with VPA (P = 0.398) compared to PBS treated 
cells (Fig. 2A). However, treatment of GL261 cells with 
VPA led to a significant decrease in colony formation 
(P = <0.001) compared to PBS control (Fig. 2A).
VPA treatment protects HT22 cells from 
radiation while sensitizing Daoy, D54 and 
GL261 cells
To determine the effect of VPA treatment on the 
cellular response to radiation, we performed clonogenic 
cell survival assays. Pretreatment of hippocampus-
Figure 2: VPA acts as a radioprotector in normal cells and radiosensitizer in cancer cells. A. Equal numbers of HT22 
or GL261 cells were plated for colony formation assay after treating with PBS or 0.6 mM VPA for 7 days. Plates were stained with 
1% methylene blue after 10 days and colonies were counted. Shown are bar graphs depicting the number of colonies for each treatment with 
SD from three experiments; *P < 0.05. B. HT22, Daoy, D54 and GL261 cell were treated with PBS (●) or 0.6 mM Valproic acid (■) for 
7 days followed by irradiation with 0, 2, 4, 6 or 8 Gy and plated for clonogenic survival assay. Shown are the surviving fractions and the 
SD from three experiments; *P < 0.05.
(Continued )
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derived HT22 cells with 0.6 mM VPA for 7 days 
significantly abrogated radiation-induced cell killing (2Gy 
P = 0.040, 4Gy P = 0.016, 6Gy P = 0.060, 8Gy P = 0.002) 
as compared to cells treated with radiation alone with a 
DMF10 of 0.87 (Fig. 2B). However, pretreatment of Daoy 
(human medulloblastoma), D54 (human glioma) and 
GL261(mouse glioma) cells with 0.6 mM VPA for 7 days 
prior to irradiation led to significant radiosensitization 
with DMF10 of 2.25, 1.49, and 2.31 for Daoy, D54 and 
GL261 cells, respectively (Fig 2B). These results indicate 
that VPA treatment protects normal hippocampal neuronal 
cells (HT22) from radiation induced cell killing, while 
radiosensitizing medulloblastoma cells (Daoy) and GBM 
cells (D54 & GL261).
VPA treatment inhibits Daoy, D54 and GL261 
cell proliferation
Having observed radiosensitization of cancer cells 
(Daoy, D54 and GL261) and radioprotection of normal 
cells (HT22) after VPA treatment in clonogenic assays, 
we wanted to ascertain if this was due to alterations in 
cell proliferation. HT22, Daoy, D54 and GL261 cells were 
treated with PBS or VPA (0.6 mM) for 7 days and then 
equal numbers of treated cells (of each cell line) were 
plated in 96-well plates. The plates were then incubated 
for 96 h, and then 20 μL of cell proliferation assay reagent 
(Promega) was added. HT22 cells treated with VPA did 
not show any differences in proliferation compared to PBS 
treated cells (P = 0.065; Fig. 2C). However, treatment 
with VPA led to reduced cell proliferation in Daoy cells 
(P = <0.002), D54 cells (P = <0.001) and GL261cells 
(P = <0.001; Fig. 2C). Thus the anti-proliferative effect 
of VPA treatment was observed only in cancer cells (Daoy 
D54 and GL261) and not in normal neuronal cells (HT22).
VPA treatment induces the accumulation of 
GL261 cells at G2/M
Since VPA treatment led to inhibition of cell 
proliferation only in cancer cells, we compared the 
effect of VPA treatment on the cell cycle distribution 
of normal vs. cancer cells. HT22 and GL261 cells were 
treated with PBS or VPA (0.6 mM) for 7 days prior to 
irradiation with 4Gy. The cells were harvested 24 h post 
irradiation, stained with propidium iodide and analyzed 
by flow cytometry. There were no significant alterations 
of cell cycle distribution in HT22 cells treated with VPA 
alone, while irradiation led to the accumulation of cells 
in the G2/M phase (40%) compared to untreated PBS 
controls (18%; P = <0.001). The accumulation in G2/M 
was abrogated when cells were treated with VPA (25%) 
Figure 2: (Continued ) C. Equal numbers of HT22, Daoy, D54 and GL261 cells were plated in 96-well plates after treatment with PBS 
or 0.6 mM VPA for 7 days and then irradiated with 4Gy. After 96 h, the cell viability was determined using a colorimetric cell proliferation 
assay. Shown are the absorbances at 490 nm; *P < 0.05
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prior to irradiation (P = <0.001; Fig. 3). Significant 
accumulation in the G2/M phase (41%) was observed 
in GL261 cells treated with VPA when compared 
to untreated PBS control cells (24%) (P = <0.001). 
A larger fraction of G2/M accumulation was observed 
when they were treated with a combination of VPA and 
irradiation with 4Gy (37%) compared to irradiation 
alone (28%; P = <0.001). This increase was however 
not statistically significant from the G2/M accumulation 
induced by VPA treatment alone (40%; Fig. 3). 
There was no major effect in the fraction of S phase 
cells in either cell line after the various experimental 
treatments.
VPA treatment inhibits both HDAC and GSK3β 
in HT22 cells
VPA inhibits the activity of histone deacetylases, 
HDACs, most likely by binding to the catalytic center of 
the enzyme [35]. VPA has also been reported to inhibit 
the activity of glycogen synthase kinase 3 beta (GSK3β) 
both in vitro [66, 67] and in vivo [67]. To determine if 
HDAC activity was inhibited by VPA treatments of HT22 
and GL261 cells we monitored the levels of acetylated 
histone H4. To determine if VPA treatment inhibits 
GSK3β in HT22 hippocampal neurons and GL261 
glioblastoma cells, we monitored the phosphorylation 
of GSK3β at ser9 that inhibits its activity and evaluated 
the levels of β-catenin as a surrogate indicator of GSK3β 
activity. Since active GSK3β phosphorylates β-catenin 
that promotes its degradation, increased accumulation of 
β-catenin correlates with decreased activity of GSK3β. 
Inhibition of HDAC activity was observed in both HT22 
and GL261 cells treated with 0.6 mM VPA for 7 days 
(Fig. 4). Interestingly, the inhibition of GSK3β by VPA 
treatment was observed only in HT22 cells and not in 
GL261cells (Fig. 4). These results indicate that VPA, 
in addition to inhibiting HDAC, also inhibits GSK3β 
in HT22 cells but not in GL261cells. Thus, the overall 
mechanisms of the action of VPA are different in these 
two cell lines. VPA treatment associated inhibition 
of GSK3β activity contributed to reduced radiation-
induced apoptosis in HT22 cells (Fig. 1C). We have 
previously shown that inhibition of GSK3β either with 
small molecule inhibitors or knockdown led to decreased 
apoptosis in normal hippocampal neurons and normal 
epithelial cells [64, 68, 69].
VPA treatment represses tumor growth in 
irradiated GL261 and D54 mouse tumor models
To determine the in vivo efficacy of VPA, two 
heterotopic glioma models GL261 (mouse) and D54 
(human) were used to generate tumor growth delay 
Figure 3: VPA treatment induces G2/M accumulation in cancer cells.  HT22 cells and GL261 cells were treated with PBS or 
0.6 mM VPA for 7 days prior to irradiation with 4 Gy. 24 h after irradiation, cells were collected, fixed and stained with PI and cell cycle 
distributions were determined by flow cytometry. Shown are the bar graphs of the average change in the fraction of G1/G0, S and G2/M 
phase cells after each treatment.
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curves (Fig. 5A & 5D). One million GL261 or D54 cells 
were injected subcutaneously in the right hind limb 
of nude mice. Tumor-bearing mice were then treated 
with PBS alone, irradiation alone (five daily fractions 
of 2 Gy), VPA (300 mg/kg) alone for 5 days, or VPA 
(300 mg/kg) for 5 days followed by irradiation (five daily 
fractions of 2Gy). In studies on the effect of VPA in mice 
models, doses ranging from 150 mg/Kg to 400 mg/Kg 
have been used [49, 67, 70]. The time required to reach 
a tumor volume of 0.6 cm3 was determined (Fig. 5B 
& 5E). An average of 13 days (GL261) and 10.2 days 
(D54) was required to reach this tumor volume in PBS 
treated mice, 20 days (GL261) and 12 days (D54) in the 
VPA treated mice, 26.5 days (GL261) and 15.2 days 
(D54) days in irradiated mice and 36.5 days (GL261) 
and 24 days (D54) in mice treated with combination of 
VPA and irradiation. Kruskal-Wallis and Tukeys pairwise 
comparisons indicated a significant difference in the 
number of days required to reach a tumor volume of 
0.6 cm3 between each treatment group (Figs 5B & 5E). 
We also analyzed the effect of the treatments on mean 
tumor growth at the midpoint (the 15th day) of the study 
(Fig. 5C & 5F). The most pronounced tumor growth 
delay was observed in tumors receiving a combination 
of VPA and irradiation (0.17 cm3 in GL261; 0.38 cm3 
in D54), followed by tumors treated with irradiation 
alone (0.34 mm3 in GL261; 0.65 cm3 in D54), followed 
by tumors treated with VPA alone (0.43 cm3 in GL261; 
0.84 cm3 in D54) followed by untreated tumors (0.86 cm3 
in GL261; 1.06 cm3 in D54). This tumor growth data 
from day 15 was also analyzed using Kruskal-Wallis 
and Tukeys pairwise comparisons. The growth of both 
GL261 and D54 tumors was significantly delayed in 
mice treated with the combination of VPA and irradiation 
when compared to mice receiving radiation alone 
(P = <0.001), or mice receiving VPA alone (P =< 0.001), 
or PBS treated controls (P = <0.001). Tumor growth 
was also significantly delayed in mice treated with 
VPA alone when compared to untreated control tumors 
(P = <0.001).
VPA treatment in combination with irradiation 
reduces intracranial tumor growth
Magnetic resonance imaging, MRI, provides 
detailed information about the anatomy and morphology 
of brain-tumors, enabling effective diagnosis and 
treatment. We used dynamic contrast-enhanced magnetic 
resonance (DCE MRI) techniques to image the effects 
of VPA on tumor growth in an orthotopic intracranial 
Figure 4: VPA inhibits both HDAC and GSK3β in normal cells, but only HDAC in cancer cells. HT22 and GL261 cells 
were treated with 0.6 mM VPA for 7 days prior to irradiation with 4 Gy. Total cellular proteins were immunobloted using antibodies against 
β-catenin, p-GSK3β (Ser9), GSK3β and Acetyl H4 to determine their levels. A representative (from 3 repeats) immunoblot is shown.
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Figure 5: VPA delays tumor growth in irradiated mouse tumor models. GL261 or D54 cells were implanted into the right flank 
of nude mice. Once the tumors were palpable, they were irradiated with 2 Gy for 5 consecutive days for a total of 10 Gy. Mice were treated 
with VPA (300 mg/Kg) or PBS 60 min prior to irradiation. Tumor volumes were measured using digital calipers. Shown are the mean tumor 
volumes with SD from each treatment group of eight mice A & D, number of days to reach a tumor volume of 0.6 cm3 B & E, *P < 0.05, 
mean tumor volume following various treatments on day 15 C & F, *P < 0.05.
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GL261 mouse tumor model that stably expressed 
luciferase. Tumor-bearing mice were screened using 
bioluminescence imaging (BLI) and stratified into 
4 groups having similar distribution of tumor volumes. 
Nine mice in each group were then treated with PBS, 
irradiation alone (five daily fractions of 2 Gy), VPA 
(300 mg/kg) alone for 5 days, or VPA (300 mg/kg) for 
5 days followed by irradiation (five daily fractions of 
2Gy). We obtained both contrast-enhanced T1-weighted 
and T2 weighted MR images for tumor growth analysis. 
We scanned the mice at three time points during these 
experiments: 1) prior to treatment (Baseline), 2) 7 days 
post treatment, and 3) 14 days post treatment (Fig. 6A). 
Regions of interest (ROI) were drawn manually around 
tumors using Image J software and the corresponding 
tumor volumes were calculated. The tumor volumes 
of all the treatment groups at the first baseline scan 
were similar, with no significant differences among the 
groups. In the second scan, seven days post treatment, 
tumor volumes for mice treated with either radiation 
(13.9 mm3 ) or VPA alone (17.9 mm3 ) were significantly 
smaller than PBS treated controls (80.3 mm3 ). The most 
significant reduction in volume was seen in mice treated 
with combination of VPA and radiation (7.4 mm3 ), 
indicating that such treatment reduced the growth of the 
glioblastoma tumor most efficiently (Fig. 6B). For the 
third scan (14 days post treatment), we scanned mice 
treated with VPA alone, irradiation alone and VPA in 
combination with irradiation. PBS treated control mice 
had to be euthanized due to tumor burden (Fig. 6A).
(Continued )
Figure 6: VPA in combination with irradiation improves survival by inhibiting tumor growth. Nude mice were implanted 
intracranially with GL261 cells stably expressing luciferase. After 10 days, mice were imaged with bioluminescence imaging and then 
serpentine sorted into four groups of nine each. Tumors were irradiated with 2 Gy or sham for five consecutive days shielding of the non-
brain areas of the body during irradiation. Mice were treated with VPA (300 mg/Kg) or PBS 60 min prior to irradiation. A. Representative, 
contrast-enhanced, T1-weighted images of mouse brain from each of the four groups (top to bottom: PBS, PBS + IR, VPA, VPA + IR) at 
baseline (left) and 7 days (middle) and 14 days (right) post treatment.
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VPA treatment in combination with irradiation 
improves survival by inhibiting tumor growth
To determine the effects of VPA on the survival of 
orthotopic tumor bearing mice, we used an intracranial 
GL261 mouse glioblastoma model stably expressing 
luciferase. Tumor-bearing mice were screened using 
bioluminescence imaging, (BLI) and stratified into four 
groups of nine mice each having similar distribution of 
tumor volumes. The mice in each group were then treated 
with PBS alone, radiation alone (five daily fractions 
of 2 Gy), VPA (300 mg/kg) alone for 5 days, or VPA 
(300 mg/kg) for 5 days followed by radiation (five daily 
fractions of 2Gy). We then analyzed the effect of the 
treatments on percent survival at the midpoint of the 
study (the 15th day). Percent survival was 13% for PBS 
treated mice, 55% for mice treated with radiation and 
44% for mice treated with VPA alone. In mice treated 
with VPA combined with radiation, 15-day survival 
was 100% (Fig. 6C). Using a Cox Proportional Hazard 
regression model we found that the mice receiving the 
combined treatment with VPA and radiation showed 
statistically significant increased survival when compared 
to PBS treated mice (P = 0.002), mice treated with 
radiation alone (P = 0.0130) or mice treated with VPA 
alone (P = 0.0140). The survival assay results indicate 
that treatment of mice with a combination of VPA and 
radiation was most effective (Fig. 6C).
DISCUSSION
Radiation therapy is an effective treatment for 
children with medulloblastoma and some forms of 
leukemia. Cranial irradiation, however, results in memory 
and learning deficits in children [71]. The age dependence 
of radiation-induced brain injury has led to delaying 
radiotherapy in infants [72]. Treatment of infants and 
children with low doses of radiation to the brain often 
leads to long lasting neurocognitive deficits that can 
become permanent [73, 74]. These neurocognitive deficits 
manifest as declines in IQ and higher unemployment 
rates as compared to children treated with chemotherapy 
alone [75, 76]. It has been proposed that the hippocampal 
neuron progenitor cells are the most affected, leading to 
the radiation-induced neurocognitive decline [77, 78]. 
Radiation-induced cognitive deficits involve apoptosis 
in the sub-granular region of the hippocampus and 
the subsequent diminished neurogenesis [78, 79]. The 
efficacy of radiotherapy can be improved by the use of 
radioprotectors that prevent radiation damage to normal 
Figure 6: (Continued ) B. Average, MRI-derived tumor volumes measured at seven days post-treatment.  
C. Kaplan-Meyer survival curves following various treatments of mice bearing intracranial tumors.
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tissues [64, 68, 80, 81]. The efficacy of radiotherapy 
can also be improved by use of chemical agents that 
specifically sensitize cancer cells to radiation [82, 83].
In the present study, mouse hippocampus and 
hippocampus-derived cells (HT22) pretreated with VPA 
were protected from radiation damage. However, such 
radioprotection was not observed in the brain cancer cell 
lines (Daoy, D54 and GL261; Fig. 2B & 2C), or in the 
GL261 and D54 tumor models (Fig. 5). The selective 
protection of hippocampal neurons could be due to 
modulations of radiation-induced pro-apoptotic signaling 
by VPA (Fig 1E). In contrast to hippocampal neurons in the 
sub-granular zone, cancer cells typically do not undergo 
apoptosis in response to ionizing radiation. Therapeutic 
radiation kills most tumor cells by post-mitotic cell death 
through mitotic catastrophe [1, 83]. Hence this differential 
response to radiation provides a means to improve the 
therapeutic effect of cranial irradiation.
Following treatment of both normal hippocampal 
cells (HT22) and glioblastoma cells (GL261) with VPA, 
we found increased levels of acetylated histone H4, 
indicating that the activity of HDACs was inhibited in 
both normal and cancer cells (Fig 4). Several phenotypes 
associated with the effects of VPA are brought about by 
its action as an inhibitor of HDACs. These include its 
cytotoxicity and perturbation on the DNA damage repair 
machinery [22, 49]. Although VPA inhibits HDAC in 
both normal and cancer cells, it selectively kills cancer 
cells [84, 85]. Several mechanisms have been proposed 
to explain the preferential selectivity killing of cancer 
cells by VPA and other HDAC inhibitors. None of the 
proposed mechanism so far can fully account for this 
generalized effect, found in multiple cell lines and tumor 
types irrespective of the different cell line specific control 
of gene transcription [84, 85]. It has been shown that 
VPA induces a specific type of DNA damage that can be 
repaired in normal cells but not in cancer cells [86]. The 
nature of such DNA damage remains to be elucidated. 
There is evidence that HDAC inhibitors lower the cell’s 
capacity to repair radiation-induced DNA damage. Such 
perturbations occur both at the level of DNA damage 
signaling and the major DNA repair pathways like NHEJ 
and HR [85, 87]. VPA and other HDAC inhibitors have 
been shown to decrease several key players in the repair 
of DNA DSB in cancer cells, at the levels of protein and/
or mRNA as well as prolonged radiation-induced repair 
protein foci. These include Ku70, Ku80, DNA PK, ligase 
IV, XRCC4, RAD 51, RAD 50, ATM, γ-H2AX, BRCA1, 
BRCA2, and 53 BP1 [46, 87]. These alterations have 
been reported in cancer cells but not in normal cells. The 
participation of the acetylation of non-histone proteins 
in the increased radiosensitivity of HDAC treated cancer 
cells has been postulated, but remains to be demonstrated 
[1, 84, 88]
We found that VPA protected normal cells from 
radiation damage, which was in part due to the attenuation 
of radiation-induced apoptosis (Fig. 1A–1D; 2B). Such 
attenuation was associated with decreased levels of Bax, 
a proapoptotic protein and increased levels of Bcl-2, an 
antiapoptotic protein (Fig. 1E). Whether the attenuation of 
radiation-induced apoptosis in the hippocampus (Figs. 1A 
& 1B) is also associated with alterations in the levels of 
these proteins remains to be determined.
We observed an increase in the phosphorylation of 
GSK3β (ser9) and stabilization of β-catenin, indicating the 
inhibition of the GSK3β activity by VPA treatment, but 
only in normal and not in cancer cells (Fig. 4). Previously 
we have shown that inhibition of GSK3β either with 
small molecule inhibitor or knockdown protected the 
hippocampal neurons from radiation-induced apoptosis 
and increased clonogenic survival [64, 89]. Further, we 
have shown that GSK 3β inhibition enhances the repair 
of DNA DSB in irradiated normal hippocampal neurons 
(HT22) but not in glioma cells (GL261 and D54). This 
effect correlated with increased efficacy of end rejoining 
by the NHEJ DSB repair pathway [89]. Hence, we 
speculate that the neuroprotection of hippocampal 
neurons in vivo involves such enhancement of the efficacy 
of the NHEJ by GSK3β. The lack of inhibition of VPA-
mediated GSK3β in glioma cells could be associated with 
the differential VPA sensitivity and radiation response of 
cancer cells.
VPA treatment has been reported to provide 
neuroprotection and improve cognitive function [67, 90]. 
The neuroprotection and improved cognitive function was 
due, in part, to inhibition of HDAC and GSK3β, which 
helped to stabilize antiapoptotic proteins like Bcl-2 in 
normal HT22 cells and prevent apoptosis ([67] Fig. 1C, 
1D & 1E). We also observed that VPA treatment reduced 
the levels of the pro apoptotic protein Bax (Fig. 1E).
VPA treatment induced a G2/M cell cycle arrest 
in GL261 cells (Fig 3). The accumulation of cells with 
G2/M DNA content is consistent with the induction of 
mitotic catastrophe as a mode of cell death in irradiated 
cells. Such effects have been reported for several glioma 
cells lines treated with VPA [91]. Taken all together, these 
results suggest that radioprotection by VPA is selective 
for hippocampal neurons, which could be mediated 
through the inhibition of HDAC and GSK3β. Although 
there has been a report that VPA protected rat brains 
from radiation-induced damage, apoptosis in cerebral 
cortex cells and long-term blood vessel damage were not 
quantitated [92].
We used 300 mg/kg VPA in the studies 
demonstrating radioprotection of normal hippocampal 
neurons and radiosensitization of glioblastoma in mice. 
VPA administered at 300 mg/Kg in mice leads to a 
serum concentration between 265–280 μg/ml [93]. At 
such serum concentrations, the maximum level of VPA 
in mouse brains is 17–30 μg/g [94, 95]. The half-life of 
VPA in mice is 1–3 hours [94], while in humans it is 9–18 
hours [96, 97]. In humans the maximum therapeutic dose 
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for epilepsy and mania is 60 mg/kg, which amounts to 
750–4000 mg/day [96]. At these doses the therapeutic 
serum levels are 50–150 μg/ml of which the levels of 
free VPA are 6–32 μg/ml [98, 99]. The levels of VPA 
in cerebrospinal fluid are usually similar to the free 
valproic acid levels [100, 101]. There are differences in 
VPA metabolism between mice and humans. Thus the 
findings in mice are difficult to extrapolate directly to 
humans [102]. Nevertheless, we speculate that the levels 
of VPA in our studies are comparable to those associated 
with therapeutic ranges in humans [102].
We found that 300 mg/kg VPA significantly 
protected mouse hippocampal neurons from radiation 
damage by attenuating apoptosis (Fig. 1A). Similar 
neuroprotection by VPA has been observed in animals 
subjected to ischemia [27, 103], traumatic brain 
injury [67], and intracerebral hemorrhage [26]. HDAC 
and/ or GSK3β inhibition has been reported in various 
studies of animals treated with 300–400 mg/kg of VPA 
[67, 103, 104].
In preclinical studies treatment with VPA was 
reported to control the growth of a variety of tumors, 
including gliomas, neuroblastomas, medulloblastomas 
and melanomas [22, 49]. VPA’s antitumor effects involve 
the modulation of various cellular and tissue pathways, 
including cell-cycle arrest, angiogenesis, apoptosis, 
differentiation, senescence and DNA repair [22]. In the 
heterotopic GL261 and D54 tumor models, mice treated 
with VPA were half as likely to develop a tumor with a 
volume greater than 0.6 cm3 than PBS treated mice (Fig. 
5B&5E). Tumor growth in mice treated with a combination 
of VPA and radiation was significantly delayed when 
compared to radiation alone, VPA alone or PBS treated 
controls (Fig. 5A & 5B, 6A & 6B). These results 
indicate that a combination of VPA with irradiation was 
significantly more effective in controlling tumor growth. 
VPA treatment alone was also effective in controlling 
tumor growth in mice and was significantly better than 
no treatment. More importantly, VPA treatment alone did 
not enhance tumor growth. These findings suggest that 
pre-treatment with VPA may significantly improve the 
response of malignant glioma to radiation therapy.
There are reports indicating that VPA alone or in 
combination therapy can increase the life span of both 
tumor bearing mice [105] and humans with brain cancer 
[48, 56, 58, 60, 61]. In clinical trials, valproic acid 
was the preferred antiepileptic agent in a combination 
therapy that utilized radiation and temozolomide 
[48]. Valproic acid has also been reported to enhance 
other combination therapies in treating intracranial 
gliomas in mice [105, 106]. We found similar results 
while analyzing DCE MRI derived tumor volumes. 
Mice treated with a combination of VPA and radiation 
showed significantly reduced tumor growth compared 
to PBS treated mice (Fig. 6A & 6B). Cox proportional 
hazards modeling was used to estimate the hazard ratio 
for overall survival between the treatment levels in the 
orthotopic intracranial tumor model. We found that mice 
with no treatment were 11.4 times (p = 0.0002) more 
likely to die than mice treated with combination of VPA 
and radiation. Mice treated with radiation alone were 
4.7 times (p = 0.0130) more likely to die than mice 
treated with combination of VPA and radiation (Fig. 6C). 
The survival of mice correlated with the tumor volume as 
seen by DCE MRI (Figs 6A&6B). Overall, these results 
indicate that VPA in combination with radiation can 
effectively control tumor growth in the brain, leading to 
improved survival.
VPA is now drawing attention due to its versatility 
in improving cognitive sequelae and protecting against 
various neurological insults, and is emerging as a 
promising drug for brain cancer treatment [56]. Our 
current findings on the radioprotective effects of VPA on 
the hippocampus and radio-sensitization effects of VPA in 
cancer cells also makes it attractive as a novel therapeutic 
strategy for the prevention of neurocognitive deficits 
resulting from cranial irradiation.
MATERIALS AND METHODS
Chemicals, cell culture and treatments
Valproic acid was purchased from Sigma. Mouse 
hippocampal neuronal cells HT22 were obtained from 
David Schubert (The Salk Institute; La Jolla, CA) and 
maintained in DMEM with 10% fetal bovine serum (FBS) 
and 1% penicillin/streptomycin (Life Technologies). 
Human medulloblastoma Daoy cells were obtained from 
ATCC and propagated in Eagle’s Minimum Essential 
Medium with 10% FBS, 2 mM L-glutamine, 1.5 g/L 
sodium bicarbonate, 0.1 mM non-essential amino acids, 
and 1.0 mM sodium pyruvate. Human glioma D54 and 
mouse glioma GL261 cell lines were obtained from 
Dr. Yancey Gillespie (University of Alabama-Birmingham, 
Birmingham, AL) and maintained in DMEM with Nutrient 
Mixture F-12 (1:1), 10% FBS, 1% sodium pyruvate and 
1% penicillin/streptomycin (Life Technologies). All cells 
were grown in a 5% CO2 incubator at 37°C. Cells were 
irradiated at a dose rate of 2.5 Gy/min using a RS2000 
160 kV X-ray Irradiator with a 0.3 mm copper filter (Rad 
Source Technologies).
Histological staining for apoptosis using TUNEL
One-week-old C57BL/6 mice pups were treated 
with daily i.p. injections of VPA (300 mg/kg) or PBS. On 
the seventh day of VPA treatment, the pups’ brains were 
irradiated with 7 Gy. Twenty four hours later, the animals 
were sacrificed and their brains were harvested and fixed 
in 10% neutral buffered formalin. The fixed brains were 
embedded in paraffin and sectioned coronally. Five micron 
thick sections were placed on Superfrost Gold Plus slides, 
stained with the DeadEnd™ Colorimetric TUNEL System 
(Promega) according to the manufacturer’s instructions, 
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and counterstained with hematoxylin. For the TUNEL 
experiments, at least three animals were used in each 
experimental group. TUNEL positive cells (TPC) were 
counted using an Olympus BX51 microscope equipped 
with an Olympus DP26 digital camera. At least three high 
power fields (HPF) per animal were scored. The average 
number of TUNEL positive cells per HPF (+/−SD) was 
calculated.
Apoptosis assays for cultured cells
Apoptosis was monitored by annexin V-APC/
propidium iodide staining using the Apoptosis Detection 
Kit according to the manufacturer’s instructions (BD 
PharMingen). Briefly, HT22 cells were treated with PBS 
or VPA (0.6 mM) for seven days, and then irradiated 
with 4Gy. Sixteen hours post irradiations aliquots of 105 
cells were incubated with Annexin V/propidium iodide 
for 15 minutes at room temperature. The cells were then 
analyzed by flow cytometry, using a two-color MACS 
FCM analysis system (Miltenyi Biotech). For each 
treatment, the average fold-increase of apoptotic cells over 
control (+/− SD) was calculated.
In separate experiments, the apoptotic nuclei 
of HT22 cells were counted after staining with 4', 
6-diamidino-2-phenylindole (DAPI). The treated cells 
were washed with PBS, fixed in 70% ethanol at room 
temperature for 10 minutes, and stained with DAPI (Vector 
Labs). The nuclear morphology was monitored using an 
Olympus BX60 fluorescence microscope equipped with 
a Retiga 2000R digital camera. Apoptosis was quantified 
by scoring the percentage of cells with apoptotic nuclear 
morphology at the single cell level. Condensed or 
fragmented nuclei were scored as apoptotic; the average 
percentage of apoptotic cells (+/− SD) was calculated in 
5–7 randomly selected HPF.
Colony formation assay
Equal numbers of GL261 and HT22 cells were 
plated on 60 mm dishes. After 4–5 h, cells were treated 
with either PBS or 0.6 mM VPA for seven days. Colonies 
were allowed to form for 10 days, after which cells were 
fixed with 70% ethanol and stained with 1% methylene 
blue. Colonies having greater than 50 cells were counted 
under a microscope and the results plotted. Experiments 
were repeated in triplicate and standard errors were 
calculated.
Clonogenic survival assay
Defined numbers of cells were plated and allowed 
to attach for 5 hours and then irradiated with 0, 2, 4, 6 
or 8 Gy. After 7–10-day incubation, plates were fixed 
with 70% ethanol and stained with 1% methylene blue. 
Colonies consisting of more than 50 cells were counted 
by viewing the plates under a StemiVD4 dissecting 
microscope (Zeiss). The survival fractions were calculated 
as (number of colonies/number of cells plated)/(number 
of colonies for corresponding control/number of control 
cells plated). The dose modifying factors at 10% survival 
(DMF10) were calculated from the survival curves by 
taking the ratio of the dose of IR that reduced survival to 
10% divided by the dose of IR that reduced survival to 
10% in the presence VPA.
Immunoblotting
Total protein was extracted from treated cells 
using the M-PER mammalian protein extraction 
reagent (Pierce). Protein concentration was determined 
using the BCA Reagent (Pierce). Protein extracts 
were analyzed using antibodies for the detection of 
phospho-GSK3βSer-9, GSK3β, β-catenin, PARP, Bcl-2 
(Cell Signaling Technologies), Acetyl H4 (Millipore) 
and Bax (Santa Cruz). Antibody against actin (Sigma) 
was used to normalize protein loading in each lane. 
Bands were visualized using the Western Lightning 
Chemiluminescence Plus detection system (PerkinElmer), 
according to the manufacturer’s protocol.
Colorimetric cell proliferation assay
Cell proliferation was determined using Cell Titer 
96 aqueous non-radioactive cell proliferation assay 
reagent (Promega). The assay was performed following 
the manufacturer’s protocol. Briefly, cells were treated 
with PBS or 0.6 mM VPA for seven days and equal 
numbers of treated HT22 (1000 cells), GL261 (2000 
cells), D54 (2000 cells) and Daoy (2000 cells) cells were 
plated in 96-well plates. The cells plated in the 96 well 
plates had the respective drug or vehicle control. Cell 
viability was determined after incubation for 96 h by 
measuring the absorbance at 490 nm with a Countess II 
L plate reader (Life Technologies). The cells in 96-well 
plate were visually scanned in an inverted microscope 
AE30 (Motic) after 96 h of incubation, to ensure that cells 
were not overly confluent in some experimental arms 
before performing the proliferation assay. Experiments 
were performed in triplicate, and both average fold 
changes relative to controls and standard errors were 
calculated.
Cell cycle analysis by flow cytometry
HT22 and GL261 cells were treated with PBS or 
0.6 mM VPA for seven days, and then irradiated with 
4Gy. Twenty-four hours post irradiation; treated cells were 
washed with PBS, fixed in 70% ethanol, and incubated 
overnight at -20°C. Cells were pelleted and resuspended 
in PBS with DNAse-free RNAse (20 μg/ml) and 
incubated at 37°C for 30 min. The cells were then stained 
with propidium iodide (50 μg/ml) at room temperature 
for 15 min and analyzed by flow cytometry. Cell cycle 
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analysis was performed using Modfit LT 3.0 software. The 
average fractions of cells in the G1, G0, G2-M and S phases 
of the cell cycle were determined and the standard error 
was calculated from three separate experiments.
Mice and treatments
C57BL/6 and Nu/Nu mice (Harlan) were used for 
animal studies. Animal procedures were approved by the 
Institutional Animal Care and Use Committee (IACUC) 
at Washington University School of Medicine in St. 
Louis. Mice were irradiated at a dose rate of 1 Gy/min 
using RS2000 160 kV X-ray Irradiator with a 0.3 mm 
copper filter (Rad Source Technologies). Mice were 
anesthetized with 2.5% isoflurane delivered using oxygen 
to immobilize the mice. Only the intended organ or the 
tumor was exposed and the rest was shielded with lead 
during irradiation.
Tumor growth delay
One million GL261 or D54 cells were injected into 
the right flank of each C57BL/6 mouse. Once tumors were 
palpable, mice were stratified into four treatment groups 
of eight each representing similar distributions of tumor 
sizes. Tumors from two groups of mice were irradiated 
with 2 Gy fractions daily for five consecutive days for 
a total of 10 Gy. These mice received either 300 mg/kg 
VPA or PBS as vehicle control by intraperitoneal injection 
(i.p.), 60 min prior to each irradiation. Two groups of non-
irradiated mice received either 300 mg/kg VPA or PBS 
alone by i.p. injection daily for five days as well. Tumor 
volumes in the mouse hind limbs were measured using 
calipers. The mean tumor volume and standard error were 
calculated for each treatment group.
Intracranial tumors
Orthotopic intracranial tumors were induced by 
stereotactically injecting 5 × 104 GL261-FG cells into 
the brains of six-week-old nude mice at a position 2 mm 
lateral to the bregma at a depth of 3 mm. The GL261-
FG cells were transduced with a lentivirus for stable 
expression of both firefly luciferase and green fluorescent 
protein. Ten days after injecting the GL261-FG cells, the 
presence of tumor was confirmed by bioluminescence 
imaging (BLI) [107]. The mice were then stratified into 
four treatment groups of nine, each representing similar 
distributions of tumor sizes. Tumors from two groups of 
mice were irradiated daily with 2Gy for five consecutive 
days for a total of 10 Gy. Mice were anesthetized and 
irradiated in a holder designed to irradiate the tumor 
region in the head only and shield the rest of the body 
with lead during irradiation. These mice received either 
300 mg/kg VPA or PBS as vehicle control i.p., 60 min 
prior to irradiation. Two groups of non-irradiated mice 
also received either 300 mg/kg VPA or PBS alone i.p., 
daily for five days as well. Over the course of 30 days, 
mice were weighed daily and monitored closely for 
the signs of pre-morbid state. These signs included 
hypoactivity, shallow, rapid and/or labored breathing, 
failure to groom, failure to respond to stimuli, hunched 
posture, dehydration and weight loss. When any of these 
signs were present, mice were euthanized. Surviving 
animals were euthanized at the end of the experiment 
(45 days after tumor implantation). Survival was 
calculated using Kaplan-Meyer analysis.
MRI imaging of intracranial tumors
Magnetic resonance images were collected using 
an Oxford Instruments 4.7-T magnet (40 cm, clear bore) 
equipped with 21-cm inner diameter, actively shielded 
Agilent/Magnex (Yarnton) gradient coils (maximum 
gradient 28 G/cm; rise time ~650 μs) driven by model 
A-240 amplifiers (Oy International Electric Company) 
The magnet/gradients were interfaced with an Agilent/
Varian Direct Drive console, and data were collected 
using a 1.5-cm OD surface coil (receive) and a 5-cm ID 
Helmholtz coil (transmit) actively decoupled coil pair as 
described [108]. Before the imaging experiments, mice 
were anesthetized with isoflurane/O2 [2–3% (v/v)], and 
maintained on isoflurane/O2 [1% (v/v)] throughout the 
experiments. Animal body temperature was maintained 
at 37°C using a pad heated with warm circulating 
water. Mice were injected i.p. with 500 μl MultiHance 
contrast agent (Bracco Imaging), diluted 1:10 in sterile 
saline, 15 minutes prior to being placed in the magnet. 
T1-weighted, spin-echo multi-slice transaxial images 
were collected with TR = 0.65 s, TE = 0.02 s, FOV = 1.5 × 
1.5 cm2, slice thickness = 0.5 mm.
Statistical analyses
The means and standard deviations (SD) of each 
treatment group were calculated for all experiments. 
The number of samples is indicated in the description 
of each experiment. Kaplan-Meier and Cox Proportional 
Hazards models were used to analyze survival data, 
while non-parametric Kruskal-Wallis analysis was used 
to compare treatment effectiveness on tumor growth 
delay. All pair-wise comparisons between treatment 
groups were adjusted using Tukey’s multiple comparison 
method. A p-value of < 0.05 was considered statistically 
significant.
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